Schroder Investment Management Group Global Blood Therapeutics, Inc. Transaction History

Schroder Investment Management Group

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$32.4 - $68.18 $225,666 - $474,873	6,965 Added 2.88%	249,107 $17 Million
Q2 2022 Aug 11, 2022	SELL	$22.3 - $37.39 $565,082 - $947,462	-25,340 Reduced 9.47%	242,142 $7.74 Million
Q1 2022 May 16, 2022	BUY	$25.68 - $35.59 $2.73 Million - $3.78 Million	106,136 Added 65.78%	267,482 $9.35 Million
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $1.45 Million - $2.34 Million	58,208 Added 56.44%	161,346 $4.72 Million
Q3 2021 Nov 12, 2021	BUY	$25.48 - $37.34 $454,384 - $665,884	17,833 Added 20.9%	103,138 $2.63 Million
Q2 2021 Aug 13, 2021	BUY	$32.46 - $43.42 $1.14 Million - $1.52 Million	35,040 Added 69.71%	85,305 $2.99 Million
Q1 2021 May 17, 2021	BUY	$38.94 - $50.85 $314,206 - $410,308	8,069 Added 19.12%	50,265 $2.05 Million
Q4 2020 Feb 16, 2021	SELL	$37.65 - $63.77 $1.51 Million - $2.57 Million	-40,225 Reduced 48.8%	42,196 $1.83 Million
Q3 2020 Nov 13, 2020	BUY	$52.76 - $74.49 $1.51 Million - $2.13 Million	28,619 Added 53.19%	82,421 $4.7 Million
Q2 2020 Aug 13, 2020	BUY	$48.73 - $81.82 $992,142 - $1.67 Million	20,360 Added 60.88%	53,802 $3.4 Million
Q1 2020 May 15, 2020	BUY	$41.72 - $87.2 $88,237 - $184,428	2,115 Added 6.75%	33,442 $1.92 Million
Q3 2019 Nov 12, 2019	BUY	$45.35 - $57.91 $61,676 - $78,757	1,360 Added 4.54%	31,327 $1.54 Million
Q2 2019 Aug 08, 2019	BUY	$52.6 - $63.29 $130,553 - $157,085	2,482 Added 9.03%	29,967 $1.58 Million
Q1 2019 May 14, 2019	BUY	$39.99 - $53.48 $1.1 Million - $1.47 Million	27,485 New	27,485 $1.46 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.